Video

Expert Addresses Add-On Approach For the Treatment of Chronic Lymphocytic Leukemia

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the highlights of the study and how the add-on approach affect the treatment of CLL.

In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.

She discussed the highlights of the study and how the add-on approach affect the treatment of CLL.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Washington D.C., USA - March 1, 2020: American Institute of Pharmacy Building in Washington, D.C., United States, the first-established professional society of pharmacists in the United States.
American Captial Building.
© 2025 MJH Life Sciences

All rights reserved.